Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

The General Hospital Corporation

Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Harvard College

The Brigham and Women's Hospital, Inc.

The Board Institute, Inc.

Matthew Meyerson

Heidi Greulich

Daniel Arie Haber

Pasi Antero Janne

Thomas J Lynch

William R Sellers

Raffaella Sordella

Jeffrey E Settleman

Daphne Winifred Bell

Timothy A Lewis

Xiaoyun Wu

Juan Guillermo Paez

Philip Lienau

Martin Lange

Alex Burgin

Bruce E Johnson

Knut Eis

Detlev Sülzle

Manuel Ellermann

Charlotte Christine Kopitz

Adrian Tersteegen

Antje Margret Wengner

Stefan Nikolaus Gradl

Ulrike Sack

Peter Hammerman

Stephan Siegel

Nathanael Schiander Gray

Ulrich Klar

Ulf Bömer

Benito Munoz

Hwan Geun Choi

Markus Berger

Volker Schulze

Ursula Mönning

Kirstin Petersen

Keith Graham

Dieter Moosmayer

Jens Schröder

William N Haining

Franziska Siegel

Michael Niehues

Bruce E Johnston

Christa Hegele-Hartung

Monica Schenone

Luc De Waal

Mohamed Abazeed

Daniel Korr

Drew Adams

Aleksandar Kostic

Alexis Ramos

Bethany Kaplan

Uwe Eberspächer

Kenneth Dale Westover

Robert Manguso

Sang Min Lim

Lara Nicole Gechijian

Jeffrey Ishizuka

Daniel P Cahill

Susan Bullman

Sam Freeman

Chandra Pedamallu

Jonathan Goldstein

Craig Strathdee

Hugh Gannon

Hassan Youssef Harb

Samuel Freeman

Phi Manh Dinh

Lucian De Waal

Ganesh M Shankar

Mikael L Rinne

Joshua M Francis

Ulricke Sack

Eis Knut

Timothy Lewis A

Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

Dihydrooxadiazinones

Bacterial species and the associated microbiome persist in tumors and metastases. Antibiotic treatment selectively reduces microbiome-induced tumor growth and can advantageously be included in treatment regimens. Accordingly, the present disclosure relates to, for example, the diagnosing cancer in a subject and providing identifying an effective treatment regimen for the subject.

Cancer diagnostic and treatment

The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).

Compounds, compositions and methods for cancer patient stratification and cancer treatment

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

Methods for predicting risk of developing colorectal cancer, for treating colorectal cancer, and reducing risk of developing colorectal cancer.

Bacterial etiology of colorectal cancer

The present invention relates to methods for identifying, assessing, preventing, and treating cancer (e.g., head, neck, and/or lung cancers in humans). A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating PD-1 and/or PD-L1 levels.

Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms

The present disclosure provides compositions and methods for the treatment of PPARG activated cancer. For example, the present disclosure provides PPARG signaling modulators for the treatment of bladder cancer. In particular, therapeutic and/or prophylactic compositions and uses of PPARG inverse-agonists are described.

Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancer

The present invention relates, in part, to methods of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an agent that inhibits or promotes the copy number, the expression level, and/or the activity of one or more biomarkers listed in Table 1 or a fragment thereof. Also provided herein are methods of detecting ADAR1 or ISG15 dependency in a high proliferation cell (e.g., a cancer cell). Also provided are methods of detected increased interferon signaling pathway activity in a high proliferation cell (e.g., a cancer cell). Included herein are methods of treating cancer with inhibitors of ADAR1 or ISG15. Methods of screening for such inhibitors are also provided herein. Methods of identifying the likelihood of a cancer to be responsive to an ADAR1 inhibitor are also provided.

Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon

The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients. 

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).

Compositions and methods for cancer expressing PDE3A or SLFN12

The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention. 

Compounds, compositions and methods for cancer treatment

Diagnosing and treating colorectal cancer

Growing community of inventors

Concord, MA, United States of America

Matthew Meyerson